Streetbeat News

Analyst Ratings

ALB

A significant bearish stance has been taken on Albemarle (NYSE:ALB) by a large investor, as indicated by unusual options activity. The sentiment among these big-money traders is split between 30% bullish and 69% bearish. The whales have been targeting a price range from $90.0 to $320.0 for Albemarle over the last 3 months. Currently, ALB's price is down -1.47% at $223.74. Keybanc maintains an Overweight rating on Albemarle with a price target of $291, while Citigroup downgraded its action to Buy with a price target of $260.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 3:18 pm

RXT

Rackspace Technology (RXT) has appointed its CTO, Srini Koushik, as the global head of its new spin-up, Foundry for Generative AI by Rackspace (FAIR). The move comes as 90% of IT decision-makers surveyed by Rackspace expressed a desire to leverage AI technologies in their cloud modernization efforts. Rackspace aims to accelerate the secure, responsible, and sustainable adoption of generative AI solutions across industries.

Portfolio Pulse from Happy Mohamed

June 28, 2023 | 3:07 pm

REGN

Regeneron Pharmaceuticals' shares are trading lower after the FDA declined to approve a higher-dose version of EYLEA. This has led to multiple analysts lowering their price targets on the stock.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 3:06 pm

SAIA

Saia (NASDAQ:SAIA) has received various analyst ratings in the last quarter, with 4 bullish, 3 somewhat bullish, 4 indifferent, and 2 somewhat bearish. No bearish ratings were observed. The average 12-month price target for Saia, according to 13 analysts, is $319.15, with a high of $390.00 and a low of $227.00. This average price target has increased by 10.12% over the past month.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 3:02 pm

LEA

Over the past 3 months, 7 analysts have published their opinion on Lear Corporation (NYSE:LEA) stock. The analysts have an average price target of $146.14, implying an upside from the current price of $140.41. The current average has decreased by 0.29% from the previous average price target of $146.57.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 3:02 pm

CI

Analysts have provided various ratings for Cigna Group (NYSE:CI) within the last quarter, with 4 bullish, 1 somewhat bullish, and 5 indifferent. The average price target is $310.9, representing a potential upside from the current price of $273.39. However, this average is a 13.8% decrease from the previous average price target of $360.67.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 3:02 pm

RETA

Reata Pharmaceuticals (NASDAQ:RETA) has received five analyst ratings in the last quarter, with one being bullish and four somewhat bullish. The average price target is $109.6, compared to the current price of $101.64, implying an upside. The average price target has increased by 17.53% over the past month.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 3:01 pm

BMY

Over the past 3 months, 4 analysts have published their opinion on Bristol-Myers Squibb (NYSE:BMY) stock. The company has an average price target of $76.5 with a high of $85.00 and a low of $65.00. This average price target has increased by 1.55% over the past month.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 3:01 pm

EYPT

EyePoint Pharmaceuticals (NASDAQ:EYPT) has received six analyst ratings in the last quarter, with five being bullish, one somewhat bullish, and none being bearish or indifferent. The average price target is $31.33, representing a significant upside from the current price of $8.0. However, this average price target is a 4.1% decrease from the previous average price target of $32.67.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 3:00 pm

ALZN

Alzamend Neuro's CEO, Stephan Jackman, is currently being interviewed on Benzinga's Live YouTube TV. The company's stock, ALZN, may be discussed during the interview.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 3:00 pm